Patent waiver not enough for vax rollout, expand production: WTO chief

Ngozi Okonjo-Iweala has argued in favour of expanding Covid-19 vaccine production and ending export restrictions, saying that getting a patent waiver would not be enough

Topics
Coronavirus Vaccine | WTO

IANS  |  Brussels 

Ngozi Okonjo
World Trade Organization (WTO) Director-General Ngozi Okonjo-Iweala

World Trade Organization (WTO) Director-General Ngozi Okonjo-Iweala has argued in favour of expanding Covid-19 vaccine production and ending export restrictions, saying that getting a patent waiver would not be enough.

She said this when answering a question on what measures are needed to accelerate equitable access to vaccines during a meeting of the European Parliament's Committee on Trade, Xinhua reported.

"Getting the Intellectual Property (IP) rights waiver for vaccines will not be enough," she said on Thursday.

Okonjo-Iweala listed three other routes, namely, reducing export restrictions and reinforcing supply chains for vaccines, working with manufacturers to expand production, and transferring the necessary technology and expertise to produce the complicated vaccines.

"The IP waiver is a hot issue on which I cannot take sides. But we need more flexibility and automatic access for developing countries, and at the same time we have to protect research and development," added the chief.

The Trade Committee is set to discuss calls for patent waivers for Covid-19 vaccines on May 25.

No consensus was reached among the members of the European Parliament (MEPs) on Wednesday regarding a proposal for a temporary waiver of patent rights for Covid-19 vaccines in a bid to speed up the global vaccine rollout.

A resolution will be put to a vote at the European Parliament's plenary session in June. Any decision on waiving IP rights will be taken by the

--IANS

int/pgh

 

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Coronavirus Vaccine
First Published: Fri, May 21 2021. 08:23 IST
RECOMMENDED FOR YOU